Dossier thématique
Dossier thématique
115
La Lettre du Cancérologue - Vol. XVI - n° 4 - avril 2007
Enfi n, parmi les facteurs de risque du cancer du côlon, l’obésité
est à nouveau incriminée par cette étude de cohorte européenne
sur 368 277 sujets, qui montre que l’indice de masse corporelle
est associé à un risque relatif de 1,55 entre le quintile le plus élevé
et le plus bas pour le cancer du côlon chez l’homme, mais pas
chez la femme. En revanche, le tour de taille et le rapport tour
de taille/tour de hanche, indicateur d’une obésité abdominale,
sont associés à un surrisque de cancer du côlon, mais pas du
rectum chez les deux sexes (26). ■
RÉFÉRENCES BIBLIOGRAPHIQUES
1. Tournigand C, Cervantes A, Figer A et al. OPTIMOX 1: a randomized study of
FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced
colorectal cancer - a GERCOR study. J Clin Oncol 2006;24:394-400.
2. Maindrault-Goebel F, Lledo G, Chibaudel B et al. OPTIMOX 2, a large ran-
domized phase II study of maintenance therapy or chemotherapy-free intervals
(CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A
GERCOR study. J Clin Oncol 2006;24:3504.
3. Labianca R, Floriani I, Cortesi E et al. Alternating versus continuous FOLFIRI
in advanced colorectal cancer (ACC): a randomized GISCAD trial. J Clin Oncol
2006;24:3505.
4. Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fl uo-
rouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fl uorouracil
and irinotecan) as fi rst-line treatment in metastatic colorectal cancer (MCC):
a multicentre randomised phase III trial from the Hellenic Oncology Research
Group (HORG). Br J Cancer 2006;94:798-805.
5. Falcone A, Masi G, Brunetti I et al. e triplet combination of irinotecan,
oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV
(FOLFIRI) as fi rst-line treatment of metastatic colorectal cancer (MCRC):
results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest
(GONO). J Clin Oncol 2006;24:3513.
6. Kemeny NE, Niedzwiecki D, Hollis DR et al. Hepatic arterial infusion versus
systemic therapy for hepatic metastases from colorectal cancer: a randomized
trial of effi cacy, quality of life, and molecular markers (CALGB 9481). J Clin
Oncol 2006;24:1395-403.
7. Ducreux M, Bouche O, Pignon JP et al. Randomized trial comparing three
diff erent schedules of infusional 5FU and raltitrexed alone as fi rst-line therapy
in metastatic colorectal cancer. Final results of the Fédération francophone de
cancérologie digestive (FFCD) 9601 trial. Oncology 2006;70:222-30.
8. Hochster H, Hart L, Ramanathan R et al. Safety and effi cacy of oxaliplatin/
fl uoropyrimidine regimens with or without bevacizumab as fi rst-line treatment
of metastatic colorectal cancer (mCRC): fi nal analysis of the TREE-Study. J Clin
Oncol 2006;24:3510.
9. Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5FU/LV
(FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with
untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB
80203 preliminary results. J Clin Oncol 2006;24:3509.
10. Dakhil S, Cosgriff T, Headley D et al. Cetuximab + FOLFOX6 as fi rst line
therapy for metastatic colorectal cancer (an International Oncology Network
study, I-03-002). J Clin Oncol 2006;24:3557.
11. Colucci G, Giuliani F, Mattioli R et al. FOLFOX-4 + cetuximab in untreated
patients with advanced colorectal cancer. A phase II study of the Gruppo Onco-
logico dell’Italia Meridionale (prot. GOIM 2402). J Clin Oncol 2006;24:3559.
12. Borner M, Mingrone W, Koeberle D et al. e impact of cetuximab on the
capecitabine plus oxaliplatin (XELOX) combination in fi rst-line treatment of
metastatic colorectal cancer (MCC): a randomized phase II trial of the Swiss
Group for Clinical Cancer Research (SAKK). J Clin Oncol 2006;24:3551.
13. Saltz L, Chung K, Timoney J et al. Simplifi cation of bevacizumab (bev) ad-
ministration: do we need 90, 60, or even 30 minute infusion times? J Clin Oncol
2006;24:3542.
14. Tabernero J, Cervantes A, Martinelli E et al. Optimal dose of cetuximab (C)
given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodyna-
mic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metas-
tatic colorectal cancer (mCRC). J Clin Oncol 2006;24:3085.
15. Siena S, Van Cutsem E, Peeters M et al. Treatment eff ect of panitumumab
in subset by epidermal growth factor receptor status from a phase 3 randomized
controlled trial. Ann Oncol 2006 ESMO 17(Suppl. 9)2006: ix249 849P.
16. Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus
leucovorin compared with intravenous fl uorouracil and leucovorin in stage II
and III carcinoma of the colon: results from National Surgical Adjuvant Breast
and Bowel Project Protocol C-06. J Clin Oncol 2006;24:2059-64.
17. Carrato A, Köhne C, Bedenne L et al., for AIO/CAO, FFCD, TTD, EORTC.
Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of
patients of UICC stage III colon cancer: preliminary analysis of the PETACC-2-
study. J Clin Oncol 2006;24:3563.
18. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radio-
therapy in rectal cancer. N Engl J Med 2006;355:1114-23.
19. Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adju-
vant fl uorouracil and folinic acid compared with surgery alone after resection
of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol
2006;24:4976-82.
20. Morris M, Platell C, de Boer B et al. Population-based study of prognostic
factors in stage II colonic cancer. Br J Surg 2006;93:866-71.
21. Sinicrope FA, Rego RL, Halling KC et al. Prognostic impact of microsatellite
instability and DNA ploidy in human colon carcinoma patients. Gastroentero-
logy 2006;131:729-37.
22. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of im-
mune cells within human colorectal tumors predict clinical outcome. Science
2006;313:1960-4.
23. Redston M, Compton CC, Miedema BW et al. Analysis of micrometastatic
disease in sentinel lymph nodes from resectable colon cancer: results of Cancer
and Leukemia Group B Trial 80001. J Clin Oncol 2006;24:878-83.
24. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of
response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
25. Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver
metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939-45.
26. Pischon T, Lahmann PH, Boeing H et al. Body size and risk of colon and rec-
tal cancer in the European Prospective Investigation Into Cancer and Nutrition
(EPIC). J Natl Cancer Inst 2006;98:920-31.